About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT04031729

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States. A proportion...

Lead sponsor: Massachusetts General Hospital•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Massachusetts General Hospital

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Ages 18 to 70 years
•NAFLD, defined by confirmed hepatic steatosis by imaging or by liver biopsy, in the absence of other causes of hepatic steatosis or significant alcohol consumption. If liver imaging or biopsy has not been performed clinically, liver ultrasound assessment will be performed as part of the screening visit.
•Early-stage liver fibrosis, defined as fibrosis less than or equal to Fibrosis Stage 3 (F3), confirmed by either (1) a recent liver biopsy or (2) a recent elastography / Fibroscan study. If no recent biopsy or elastography/Fibroscan have been performed, a Fibroscan will be performed as part of the screening visit.

Exclusion Criteria

•Liver fibrosis stage \> 3
•Current aspirin use
•Contraindications to aspirin use
•Contraindications to magnetic resonance imaging (MRI)
•Pregnancy or desire to become pregnant
•Breastfeeding

Related studies

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NCT03587831 · NASH - Nonalcoholic Steatohepatitis

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784 · MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), and more

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891 · Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss

NCT07237750 · Overweight and/or Obesity, Metabolic Syndrome, and more

RECRUITINGPhase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 24, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment80

Start dateSep 2019

Last updatedMay 24, 2024

Condition

Nonalcoholic Fatty Liver Nonalcoholic Steatohepatitis

Locations shown

Massachusetts General Hospital

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 24, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions